Market Overview

Organovo Continues To Gain On Positive 3D Tissue Results

Related ONVO
Unique 3D Startups And The Public Companies That Should Buy Them
Organovo Up 19% #PreMarket; In Research Pact With Johnson & Johnson Unit

Shares of Organovo (NYSE: ONVO) gained another nine percent in Friday's trading following an 11.7 percent gain on Thursday.

Organovo reported positive results from a collaborative study using the company's 3D Human Liver Tissues on Thursday. The news drove shares up more than 12 percent, with the stock closing at $8.20.

Dr. Adrian Roth, Head of Mechanistic Safety for Roche Pharmaceutical Research and Early Development at the Roche Innovation Center Basel, presented at the 3D Cell Conference in Germany on June 25. The results concluded that Organovo's 3D Liver was able to distinguish between a hepatoxic drug from a similar non-toxic chemical analog.

Shares of Organovo closed at $8.60, up 4.88 percent.

Posted-In: Long Ideas News Short Ideas Global Trading Ideas

 

Related Articles (ONVO)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters